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Guest Editorial
The Journal of Molecular Diagnostics: From
Conception to Contract
The birth of a journal takes great forethought, passion,
and patience, and the creation of The Journal of Molecular
Diagnostics was no exception. For the members of the
Association for Molecular Pathology (AMP), having their
own place to publish advances in molecular diagnostics
meant not only finding a publishing partner but also de-
fining the Journal’s direction. The society’s members and
leaders showed great enthusiasm during this process,
along with persistence, in bringing their endeavor to
fruition.
First Steps
It was fitting that the final principles governing an affilia-
tion agreement to establish what has become AMP’s
companion publication, the JMD, were agreed on in 1998
during the term of AMP’s third President, Cheryl Willman;
she first proposed that we consider a society-sponsored
journal during AMP’s business meeting in 1996. This
proposal seemed an ambitious undertaking for a then
one-year-old society, but the society believed in the need
for a journal, so Jeff Kant, President at the time, ap-
pointed Margaret (Peggy) Gulley, who would succeed
him as President in 1997, to chair the ad hoc Journal
Affiliation Committee to explore the possibilities.
Peggy was joined on the committee by Tom Williams,
Tony Killeen, and Rita Braziel. They approached six jour-
nals about possibilities ranging from forming a society-
journal affiliation to publishing a new journal; all but one
journal indicated moderate to significant interest. After
deliberation, the Journal Affiliation Committee recom-
mended that AMP pursue discussion with the American
Society for Investigative Pathology (ASIP), which had
proposed a companion journal to its highly regarded The
American Journal of Pathology (AJP) and had also shown
interest through administrative and financial support of
AMP as a fledgling professional society. While other jour-
nals were all considered potentially favorable, the possi-
bility of AMP having full or partial ownership of its own
journal was particularly attractive. Prescient concerns
were raised around potential compatibility of the organi-
zational “cultures” of AMP and ASIP (see below).
Partnership
A negotiating team of the then current President (Peggy
Gulley), Past-President (Jeff Kant), and President-Elect
(Cheryl Willman) was appointed by the AMP Council in
1997, and by early fall, a first draft of organizing ideas
was sent to the ASIP Publications Committee (chaired by
Sandra Wolman) and governing Council, as well as the
AJP’s Editor-in-Chief Nelson Fausto. AMP’s primary aims
were a separate journal (title to be determined), immedi-
ate listing of the new journal in Index Medicus, and edito-
rial control to reflect the interests and priorities of AMP. To
accomplish the goal of immediate listing in Index Medi-
cus, it was proposed that the new journal be published
initially as The American Journal of Pathology, Part B.
ASIP’s primary goals were a quality peer-reviewed jour-
nal reflecting the stature of the AJP, inclusion of the
companion journal in library subscriptions to the AJP, and
distribution of the companion journal to ASIP members.
Both societies agreed that the Editor-in-Chief of the AJP
would initially direct broad editorial matters of the com-
panion journal, and a Senior Associate editor would over-
see day-to-day issues. AMP and ASIP would approve the
Senior Associate Editor, as well as other Associate Edi-
tors to be appointed by the Senior Associate editor.
These steps made for a good starting point.
Both societies agreed on a quality journal in molecular
diagnostics focusing on “basic or translational research
in the molecular diagnosis of disease,” but the devil
would prove to be in the details, which themselves were
shaded by the perspectives of each society. Although
there were some dual AMP/ASIP members, the majority
of society memberships were largely nonoverlapping. As
a companion journal to the AJP, some ASIP leaders felt
the companion journal should belong to ASIP; others
initially recommended that all AMP members should re-
ceive AJP as part of the arrangement, at an additional
cost. Some AMP members felt that ASIP, as an estab-
lished society of successful scientists with a high-quality
journal, was occasionally paternalistic about whether
AMP, as a young society of clinically focused members,
could bring the requisite quality to this enterprise that
would, at least initially, bear the AJP moniker. On the
other side, AMP members, new to professional society
governance and publishing, but not lacking in enthusi-
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asm for a rapidly expanding field, felt certain of providing
the essential elements of success for the venture and
thus saw AMP as the eventual majority or sole owner of
the new journal. Thinking back, there was also incom-
plete appreciation within AMP of an underlying desire by
many in ASIP leadership to foster further productive in-
teractions and ties between the two societies.
Perhaps because there lacked an early face-to-face
meeting of the principal negotiators, key underlying is-
sues remained obscured in text proposals over the first 3
months of 1998 until what was in retrospect the fortuitous
“Massacre of April 18.” A meeting of AMP and ASIP
negotiators was scheduled for that day in San Francisco
at the annual ASIP meeting, to which Jeff Kant dutifully
flew, not knowing the meeting had been canceled the
preceding day. Serendipitously, a shared lunch a few
days later with Hal Dvorak, then President of ASIP, re-
sulted in several key issues being clarified. These prin-
ciples were refined by negotiators and the respective
Councils over the next 6 months to become the founda-
tion of a contract (which has since been renewed)
whereby both societies equally own and share the risks
and benefits of an independent journal that capitalizes on
the operational and editorial strengths of the AJP while
producing high-quality content appropriate to AMP inter-
ests. Further ensuring equal representation of AMP and
ASIP, the societies designated the Joint Journal Over-
sight Committee to supervise the Journal, a foundation
that operates smoothly to this day with the Chair alternat-
ing between AMP and ASIP.
In the process of developing the intersociety agree-
ment, tense and sometimes comical scenes transpired.
Fran Pitlick, Executive Officer of AMP and ASIP, offered a
voice for calm and reason while Priscilla (Smith) Mark-
wood, Managing Editor of the AJP, provided essential
details and guidance. Cheryl Willman and Vinay Kumar,
AMP and ASIP Presidents, respectively, provided en-
couragement to the initial Joint Journal Affiliation Com-
mittee (Aggie Kane, Jeff Kant, Mark Sobel, Dan Farkas,
and Linda McManus) to address such important issues
as name, price, number of pages, impact factor, online
presence, subscription numbers, and advertising in-
come. It was clear that success in the face of initial
uncertainties rested on mutual respect, compromise, and
growth of the relationship between ASIP and AMP over
time. Cautious optimism prevailed, and Jeff Kant and
Linda McManus helped by providing relief with humor,
eg, using “financial conservatism that would curl a Re-
publican’s toes” or “moving like a slug in the salt flats.” All
things considered, the short interval between initial face-
to-face discussions and coming to a final agreement
(about 6 months) was quite amazing and a positive sign.
Moving Forward
Naming the fledgling journal required serious consider-
ation. Some candidates included Clinical Molecular Diag-
nostics, Modern Diagnostic Pathology, and Molecular Diag-
nosis of Disease, as well as several more “psychedelic”
suggestions offered lightheartedly by Dan Farkas. The
Journal of Molecular Diagnostics was a late entry, and it
took persistence, support from ASIP members, and lin-
guistic consultation from Jeff Kant’s department Chair,
whose mother tongue is Greek, to gain the day for “diag-
nostics” over “diagnosis.” There was a conscious choice
to omit “clinical” from the title to provide a broad venue for
manuscripts from fundamental molecular mechanisms of
disease to clinical applications.
We knew from budget projections during negotiation
that the JMD would operate at a modest loss initially and
probably for some time. However, the net cost per mem-
ber was far less than it would have been for a journal that
AMP or ASIP did not own. Having overseen the exhibit
program at the 1997 AMP annual meeting, Jeff Kant was
aware of the potential interest for commercial advertising
in the new journal in excess of what a basic science
journal typically experiences, suggesting great potential
for financial growth. This resulted in the “margarita bet”
with his co-author, which is still owed but never collected
because it’s more fun to hold in reserve!
Ten years, 10 volumes, from quarterly to bimonthly;
there’s much reason for celebration. The JMD continues
to grow as a vital journal that AMP and ASIP, now very
comfortable with each other, embrace and promote for its
merit to the scientific and clinical communities served by
each society as well as its value to the broader pathology
and medicine arenas.
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